Supriya Lifescience Ltd., a global API manufacturer with presence in over 86 countries, reported its highest-ever annual revenue of ₹696.48 crore in FY25, marking a 22% year-on-year growth.
The company also saw strong margin expansion, with EBITDA rising 50.7% to ₹260.80 crore and EBITDA margin improving to 37.4%, up from 30.3% in FY24. PAT surged 57.8% to ₹187.96 crore, pushing PAT margin to 27.0%.
Quarterly Highlights (Q4 FY25):
-
Revenue: ₹184.11 crore, up 16.4% YoY
-
EBITDA: ₹67.58 crore (margin 36.7%)
-
PAT: ₹50.38 crore, up 38.4% YoY
-
EPS: ₹6.29 vs ₹4.59 in Q4 FY24
Chairman and Whole-Time Director Dr. Satish Wagh said the record-breaking year is a result of Supriya’s diversified product mix, operational efficiency, and strategic focus on high-value therapies. He emphasized stronger penetration in regulated markets and robust backward integration as key growth drivers.
Looking Ahead:
The company is focused on innovation, expanding its global footprint, and delivering sustainable, long-term value to stakeholders.
